Fabhalta®: Study Sheet - English
Study sheet
Download
To receive by post, click on the "Add to card" button below
.field-name-field-np4-expiry-date {display:none;}
Fabhalta®: Safety Card - Dutch
Patient safety card To receive by post, click on the "Add to card" button below Find Fabhalta material on FAGG.be .field-name-field-np4-expiry-date {display:none;}Fabhalta®: RMP package - German
The RMP material contains 2 documents Patient/Caregiver brochure Patient Safety card To receive by post, click on the "Add to card" button below .field-name-field-np4-expiry-date {display:none;}Xolair® SAA - initial reimbursement request annex A (French)
Download French document .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button belowSafety Profile - Jakavi
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...Twitter Linkedin Facebook Pinterest Google plusReimbursement - Jakavi
Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 and for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusDose recommendation - Jakavi
Patient Resources - Jakavi
Indications - Jakavi
Myelofibrosis (MF) Jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera...
Twitter Linkedin Facebook Pinterest Google plus